Sema4 Receives $121 Million in its Series C Funding

Sema4 Receives $121 Million in its Series C Funding

Healthcare Tech Outlook | Tuesday, August 11, 2020

Sema4 oversubscribed Series C financing of $121 million at a post-money estimation of over $1 billion.

FREMONT, CA: Sema4 is a patient-centric health intelligence company. They recently announced the funds raising $121 million in a Series C funding led by BlackRock. The new investors consisted of Deerfield Management Company and Moore Strategic Ventures. Sema4s Series C financing has come after they accomplished considerable achievements subsequent its first round of external financing (Series B) in which the organization could raise just over $120 million less than 12 months ago. Every one of the investors from the Sema4’s first round of external funding contributed to the second round. It even included companies such as Blackstone, Oak HC/FT, Section 32, Decheng, and Connecticut Innovations.

Therefore, as a part of the pronouncement, Andrew Elbardissi, MD Partner at Deerfield, has also joined the Sema4s board of directors. Recently Sema4 even included many other important people on board like Mike Pellini as the MD from Section32, and he was also the former CEO of Foundation Medicine, former Principal Deputy Commissioner at the FDA Rachel Sherman, and Marty Chavez who was the former CFO of Goldman Sachs.

William Abecassis, Head of Innovation Capital at BlackRock, said, “Sema4 is a leader at the forefront of one of the most exciting intersections in healthcare the application of technology, AI and machine learning to help improve patient outcomes. We are excited to support this talented management team as Sema4 begins its next phase of growth.”

“This investment is exciting for the significant financial resources it provides Sema4 for our continued rapid growth and accelerated investment, and also for the world-renowned partners it brings to our team,” said Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4. “I look forward to working with our new and existing investors who collectively have deep expertise in the life and data sciences as we create cutting-edge precision medicine solutions for providers and patients to dramatically improve health outcomes.”

Weekly Brief